AIarXiv
Ranked by formulaVerdict: NotableProCARE: Real-World Study Automation via Profile-Grounded Evidence Contracts
Real-world studies (RWS) analyze routinely collected healthcare data, such as electronic health records and insurance claims, to estimate treatment effects, monitor safety, and identify risk factors outside randomized…
VerdictWorth a reader's time today.
Abstract
Real-world studies (RWS) analyze routinely collected healthcare data, such as electronic health records and insurance claims, to estimate treatment effects, monitor safety, and identify risk factors outside randomized trials. Automating RWS with large language model agents is appealing but brittle: valid analyses depend on dataset-specific clinical semantics, including index dates, follow-up windows, patient/event-level units, and outcome boundaries that are often implicit in observational data. This leads to schema mismatches, temporal errors, inconsistent analytical granularity, and unsupported clinical claims. We present ProCARE, a profile-grounded framework that reformulates RWS automation as constrained compilation. ProCARE converts heterogeneous data profiles into Evidence Contracts specifying available variables, temporal attributes, distributions, and evidentiary limits, and compiles study objectives into RWS-IR, a strongly typed intermediate representation for variables, time relations, analysis units, and statistical tasks. Deterministic validation and localized repair then check and revise generated workflows across schema mapping, cohort construction, variable derivation, analysis, and interpretation. On 36 EHR-based benchmark tasks, ProCARE outperforms strong LLM-agent baselines in code executability, semantic consistency, and conclusion traceability, with automated violation diagnoses showing moderate-to-substantial agreement with blinded expert review.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ███░░ 3 | 24% | A method or resource many groups across the field will adopt within a year. |
| Magnitude | ███░░ 3 | 18% | Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem. |
| Evidence | ████░ 4 | 14% | Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial. |
| Novelty | ██░░░ 2 | 16% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 18% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 10% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose); gains (outperforms); design (randomized, blinded); verification (code released); stakes (general AI, prevention or cure).
How the score was computed
- Merit
- 5.6 / 10
- Adjusted merit
- 4.7 / 10
- Attention
- 0%
- Freshness
- 45%
- Citations0 (reference 15, via semantic-scholar, Oct 15, 2026, 06:17 UTC)
- Influential citations0 (reference 3, via semantic-scholar, Oct 15, 2026, 06:17 UTC)